<DOC>
	<DOCNO>NCT01377467</DOCNO>
	<brief_summary>The primary objective study examine effect denosumab lumbar spine bone mineral density ( BMD ) one year treatment newly transplant renal allograft recipient . Secondary endpoint include BMD change total hip femoral neck , change body height , change bone mineral metabolism parameter , incidence fracture , allograft function one year . Safety measurement include occurrence rejection episode , infectious complication , graft loss mortality . - Trial medicinal product</brief_summary>
	<brief_title>Denosumab Prevention Osteoporosis Renal Transplant Recipients</brief_title>
	<detailed_description>Renal allograft recipient high risk suffer substantial loss bone mineral density ( BMD ) within first year kidney transplantation . This loss BMD correlate increase risk development osteoporosis worsen pre-existing osteopenia/osteoporosis , heighten risk subsequent occurrence fracture . Renal allograft recipient often treat calcium vitamin D preparation prevent BMD loss . The addition bisphosphonates improve BMD . However , bisphosphonates potentially nephrotoxic promote adynamic bone disease , therefore regularly prescribe . Receptor Activator Nuclear factor- Kappa-B Ligand ( RANKL ) key molecule mediate development , activity , survival osteoclast . Osteoporosis result part increase osteoclastic bone resorption , therefore inhibition RANKL activity become obvious therapeutic strategy prevent bone mineral density ( BMD ) loss development osteoporosis . The novel anti-osteoporotic drug denosumab ( trade name ProliaÂ® ) fully human monoclonal antibody RANKL . By inhibit development activity well reduce survival osteoclast decrease bone resorption increase bone density . The hypothesis present study denosumab beneficial effect loss BMD first year renal transplantation . The preservation BMD surrogate parameter , generally predict subsequent improvement occurrence rate fracture . The hypothesis test study effect denosumab BMD newly transplant renal allograft recipient . The purpose present trial study effect denosumab BMD kidney allograft recipient . The study participant treat 1 year , receive total 2 injection standard 60 mg dose baseline 6 month . Ninety sequential renal allograft recipient randomize 1:1 receive two subcutaneous 60 mg denosumab injection within 14 day 6 month follow renal transplantation , treatment . All patient also receive oral standard treatment 1000 mg calcium plus 800 IU vitamin D .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>The key inclusion criterion : 1 . Male female adult de novo kidney , kidneypancreas kidneyislet , kidneyliver transplant recipient 2 . Functioning graft within 28 day transplantation ( creatinine decrease &lt; 200 micromol/l without need dialysis ) 3 . Being standard triple immunosuppression include calcineurin antagonist ( cyclosporine tacrolimus ) , mycophenolate ( MMF MPA ) steroid , without induction treatment basiliximab antithymocyte globulin Key exclusion criterion : 1 . Age &lt; 18 year 2 . Rising creatinine initial drop &lt; 200 micromol/l creatinine &gt; 200 micromol/l baseline 3 . Evidence early acute rejection , either suspect clinically and/or proven biopsy 4 . Presence severe osteoporosis evidence T score &lt; 4 hip , femoral neck 4 vertebra L1 L4 5 . Evidence severe hyper hypoparathyroidism ( iPTH &gt; 800 ng/l &lt; 10 ng/l ) 6 . Hypocalcemia ( total calcium &lt; 1.8 mmol/l ) hypercalcemia ( total calcium &gt; 2.7 mmol/l ) 7 . Steroidfree de novo immunosuppression scheme</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>Osteopenia</keyword>
	<keyword>Denosumab</keyword>
	<keyword>Transplantation</keyword>
	<keyword>Kidney</keyword>
</DOC>